Back to search

University of Edinburgh

Characterising a novel tumour suppressor in liver cancer

Abstract

dc:description.abstract

Liver cancer is among the leading causes of cancer mortality worldwide, with hepatocellular carcinoma (HCC) accounting for 75-90% of primary liver cancers. In the United Kingdom, HCC incidences have risen by 167% since the 1990s, paralleling increases in alcohol use, obesity, diabetes, smoking, metabolic dysfunction-associated steatotic liver disease (MASLD), and cirrhosis, alongside established risks such as chronic HBV/HCV infection and aflatoxin exposure. HCC progression is accompanied by metabolic rewiring including increased lipogenesis, glycolysis, tricarboxylic acid (TCA) cycle activity, and reactive oxygen species production which are often linked to epigenetic alterations in histone modifications, DNA methylation, and transcription factor regulation. JMJD5 is a 2-oxoglutarate-dependent Jumonji C-domain dioxygenase that requires molecular oxygen, 2-oxoglutarate, and Fe(II) for catalysis. It functions as an arginine hydroxylase and has been reported to display histone demethylase activity, with roles in DNA damage repair, cell-cycle control, development, and metabolism. JMJD5 is highly enriched in normal liver tissues and is reduced in HCC, where low expression is associated with hypoxic tumours and poor survival. Yet its molecular substrates and functions in liver cancer remain elusive. Here, using CRISPR-Cas9-mediated JMJD5 ablation in HepG2 cells and complementary mouse models, we combine quantitative proteomics, untargeted metabolomics, and 13C-glucose tracing to define JMJD5-dependent programs. JMJD5 loss altered the regulation of >300 proteins, including factors involved in hepatic maintenance, xenobiotic and one-carbon metabolism, DNA damage repair, histone methylation, and transcriptional regulation. Metabolomics revealed increased flux through glycolysis, the TCA cycle, the pentose phosphate pathway, and one-carbon metabolism. JMJD5 loss also increased methyl donors and the abundance of methyltransferases (e.g., DNMT3A, NSD2, DOT1L), consistent with epigenetic reprogramming. These changes were largely recapitulated in vivo, underscoring physiological relevance. Mechanistically, we identify a JMJD5-ISY1-PRMT6 axis: JMJD5 hydroxylates an arginine residue on ISY1, enabling ISY1 to bind protein arginine methyltransferase 6 (PRMT6) and inhibit its activity. Genetic ablation of PRMT6 largely rescued the molecular phenotypes caused by JMJD5 loss. Collectively, our findings support a tumour-suppressive role for JMJD5 in maintaining hepatic identity and metabolic homeostasis. By establishing ISY1-mediated inhibition of PRMT6 as a key downstream effector of JMJD5, we present PRMT6 as a potential therapeutic target in HCC with JMJD5 deficiency.

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Khan, Abu Zaid
Advisors dc:contributor.advisor
  • Von Kriegsheim, Alex
  • Boulter, Luke

Subjects

dc:subject × 6

Rights

Language dc:language.iso
en

Identifiers

dc:identifier.*

Chain of custody

source
Harvested from
University of Edinburgh
Base URL
era.ed.ac.uk/server/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
citation

Khan, Abu Zaid. Characterising a novel tumour suppressor in liver cancer. 2026. https://era.ed.ac.uk/handle/1842/44812